Drug Profile


Alternative Names: Deuterated pirfenidone; Deuterium-substituted pirfenidone; Pirfenidone deuterated; SD-560

Latest Information Update: 10 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Auspex Pharmaceuticals
  • Developer Teva Pharmaceutical Industries
  • Class Anti-inflammatories; Antifibrotics; Organic deuterium compounds; Pyridones; Small molecules
  • Mechanism of Action Collagen inhibitors; Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis

Most Recent Events

  • 05 May 2015 Auspex Pharmaceuticals has been acquired by Teva Pharmaceutical Industries
  • 16 Dec 2014 Phase-I clinical trials in Idiopathic pulmonary fibrosis (In volunteers) in USA (PO)
  • 27 Mar 2014 Preclinical trials in Fibrosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top